---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-21-050817"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2021-09-30T23:59:59+00:00"
generated_at: "2026-06-29T00:20:43.956568+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx appoints Edward Stelmakh CFO/COO; Doug Baker transitions to EVP of finance

## Summary
- Edward Stelmakh named CFO/COO effective Oct 11, 2021; Doug Baker becomes EVP of finance and accounting.
- Stelmakh's annual base salary set at $425,000; target bonus 50% of base; one-time equity grant valued at $3.0 million.
- Stelmakh brings 30+ years pharma experience, most recently as CFO/COO at Otsuka America Pharmaceuticals.
- Severance includes 12 months base salary if terminated without cause, plus COBRA coverage for 12 months.

## SEC filing metadata
- accession: 0001213900-21-050817
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2021-09-30T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390021050817/0001213900-21-050817-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390021050817/ea148140-8k_optimizerx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-21-050817
- JSON: https://secwatch.observer/filing/0001213900-21-050817.json
- Plain text: https://secwatch.observer/filing/0001213900-21-050817.txt

## Key facts
- Executive change
  Douglas P. Baker changed role as EVP of finance and accounting at OptimizeRx Corp.
  - Action: transitioned
  - Role: EVP of finance and accounting
  source text: On September 24, 2021, the Company and Douglas P. Baker, the Company’s current Chief Financial Officer, agreed that Mr. Baker will transition into the position of EVP of finance and accounting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390021050817/0001213900-21-050817-index.htm
- Executive change
  Edward Stelmakh was appointed as Chief Financial Officer/Chief Operations Officer at OptimizeRx Corp.
  - Action: appointed
  - Role: Chief Financial Officer/Chief Operations Officer
  source text: On September 30, 2021, OptimizeRx Corporation (the “Company”) announced that Edward Stelmakh has been appointed to serve as the Company’s Chief Financial Officer/Chief Operations Officer, effective as of October 11, 2021 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390021050817/0001213900-21-050817-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.